{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=32",
    "query": {
      "condition": "Phase II",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 21412,
    "total_pages": 2142,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T17:56:11.874Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06987513",
      "title": "RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder (AUD)"
      ],
      "interventions": [
        {
          "name": "Pemvidutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Altimmune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-05-15",
      "completion_date": "2026-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "University Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06987513"
    },
    {
      "nct_id": "NCT05330182",
      "title": "LMN-201 for Prevention of C. Difficile Infection Recurrence",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Clostridioides Difficile Infection"
      ],
      "interventions": [
        {
          "name": "LMN-201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lumen Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 375,
      "start_date": "2024-08-29",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 15,
      "location_summary": "Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Burr Ridge",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05330182"
    },
    {
      "nct_id": "NCT06984523",
      "title": "Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomeningeal Metastasis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Leptomeningeal Metastasis"
      ],
      "interventions": [
        {
          "name": "Varian Eclipse",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-05-14",
      "completion_date": "2028-05-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06984523"
    },
    {
      "nct_id": "NCT02315196",
      "title": "Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Estrogen Receptor-negative Breast Cancer",
        "HER2-negative Breast Cancer",
        "Progesterone Receptor-negative Breast Cancer",
        "Stage IIA Breast Cancer",
        "Stage IIB Breast Cancer",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Triple-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "epirubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 62,
      "start_date": "2015-02-25",
      "completion_date": "2041-07",
      "has_results": true,
      "last_update_posted_date": "2023-03-29",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315196"
    },
    {
      "nct_id": "NCT05531786",
      "title": "Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Graft vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Pacritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 50,
      "start_date": "2023-03-06",
      "completion_date": "2027-07-22",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Bethesda, Maryland",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05531786"
    },
    {
      "nct_id": "NCT05983770",
      "title": "Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "AT-1501",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eledon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 127,
      "start_date": "2023-08-30",
      "completion_date": "2025-09-25",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 27,
      "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 23 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05983770"
    },
    {
      "nct_id": "NCT01700673",
      "title": "Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-06",
      "completion_date": "2020-06",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01700673"
    },
    {
      "nct_id": "NCT07419373",
      "title": "ARN-75039 Lassa Fever Treatment in West Africa",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lassa Fever"
      ],
      "interventions": [
        {
          "name": "ARN-75039 high",
          "type": "DRUG"
        },
        {
          "name": "Intravenous ribavirin",
          "type": "DRUG"
        },
        {
          "name": "ARN-75039 low",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arisan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2026-02-14",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 1,
      "location_summary": "Carlsbad, California",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07419373"
    },
    {
      "nct_id": "NCT02425683",
      "title": "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms",
        "Adenocarcinoma of the Colon",
        "Adenocarcinoma of the Rectum"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Oncology Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-03-26",
      "completion_date": "2017-09-21",
      "has_results": false,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 1,
      "location_summary": "Including Dallas, TX, Ocala, FL, Denver, CO, Florida",
      "locations": [
        {
          "city": "Including Dallas, TX, Ocala, FL, Denver, CO",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02425683"
    },
    {
      "nct_id": "NCT02915783",
      "title": "A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Clear Cell Renal Cell Carcinoma (nccRCC)"
      ],
      "interventions": [
        {
          "name": "lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2017-02-20",
      "completion_date": "2021-11-02",
      "has_results": true,
      "last_update_posted_date": "2023-01-17",
      "last_synced_at": "2026-11-15T17:56:11.874Z",
      "location_count": 8,
      "location_summary": "Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915783"
    }
  ]
}